Format

Send to

Choose Destination
Anticancer Res. 2015 Jan;35(1):555-62.

Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.

Author information

1
Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
2
Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo, Japan Department of Oncology, The Jikei University School of Medicine, Tokyo, Japan shigeo_koido@jikei.ac.jp.
3
Department of Oncology, The Jikei University School of Medicine, Tokyo, Japan.
4
Research and Development Division, Tella Inc., Tokyo, Japan.
5
Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
6
Department of Advanced Immunotherapeutics, Kitasato University School of Pharmacy, Tokyo, Japan.
7
Department of Functional Diagnostic Science, Graduate School of Medicine, Osaka University, Osaka, Japan.

Abstract

BACKGROUND/AIM:

Treatment combining dendritic cells (DCs) pulsed with three types of major histocompatibility complex (MHC) class I and II (DC/WT1-I/II)-restricted Wilms' tumor 1 (WT1) peptides with chemotherapy may stabilize disease in pancreatic cancer patients.

MATERIALS AND METHODS:

Laboratory data from seven patients with pancreatic cancer who underwent combined DC/WT1-I/II vaccination and chemotherapy were analyzed. The DC phenotypes and plasma cytokine profiles were analyzed via flow cytometry.

RESULTS:

The post-treatment neutrophil to lymphocyte (N/L) ratio was a treatment-related prognostic factor for better survival. Moreover, the mean fluorescence intensities (MFIs) of human leukocyte antigen (HLA)-DR and cluster of differentiation (CD)83 on DCs were significantly increased after chemoimmunotherapy. Interestingly, interleukin (IL)-6 level in plasma was significantly increased after chemoimmunotherapy in non-super-responders.

CONCLUSION:

An increased N/L ratio, as well as HLA-DR and CD83 MFI levels may be prognostic markers of longer survival in patients with advanced pancreatic cancer who undergo chemoimmunotherapy.

KEYWORDS:

Cytokine; MHC class II; WT1; chemoimmunotherapy; dendritic cell; pancreatic cancer; vaccine

PMID:
25550602
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center